Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Assets (2016 - 2025)

Guided Therapeutics' Current Assets history spans 16 years, with the latest figure at $605000.0 for Q4 2025.

  • On a quarterly basis, Current Assets fell 49.46% to $605000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $605000.0, a 49.46% decrease, with the full-year FY2025 number at $605000.0, down 49.46% from a year prior.
  • Current Assets hit $605000.0 in Q4 2025 for Guided Therapeutics, down from $799000.0 in the prior quarter.
  • Over the last five years, Current Assets for GTHP hit a ceiling of $3.5 million in Q3 2022 and a floor of $605000.0 in Q4 2025.
  • Historically, Current Assets has averaged $1.5 million across 5 years, with a median of $1.4 million in 2021.
  • Biggest five-year swings in Current Assets: surged 705.04% in 2021 and later plummeted 54.8% in 2023.
  • Tracing GTHP's Current Assets over 5 years: stood at $1.6 million in 2021, then surged by 83.51% to $3.0 million in 2022, then plummeted by 53.63% to $1.4 million in 2023, then decreased by 14.07% to $1.2 million in 2024, then plummeted by 49.46% to $605000.0 in 2025.
  • Business Quant data shows Current Assets for GTHP at $605000.0 in Q4 2025, $799000.0 in Q3 2025, and $811000.0 in Q2 2025.